Aurobindo Upbeat On Outlook, Transfers Biologics Biz

Seeks FDA Desk Reviews For Three Units

 
• By Vibha Ravi

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Business growth
Aurobindo Looks For Growth As It Carves Out Biologics Business • Source: Shutterstock

Aurobindo Pharma Ltd. doesn’t see major disruptions to its business on account of COVID-19 and expects its strong showing in the fourth quarter of fiscal 2020 to continue in the current fiscal year as well. A growth in volumes, backed by 50-60 product launches, should see gross margins of 58-59%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip